---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-252361"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:40:13.439025+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Amgen completes $27.8B acquisition of Horizon Therapeutics at $116.50/share

## Summary
- Paid $26.7B cash for Horizon shares; borrowed $4B under term loan to fund portion of consideration.
- Acquisition expected to be accretive to non-GAAP EPS starting in 2024; Amgen to update FY2023 guidance on Q3 call.
- Adds rare-disease drugs TEPEZZA, KRYSTEXXA, UPLIZNA to Amgen's inflammation portfolio.

## SEC filing metadata
- accession: 0001193125-23-252361
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312523252361/0001193125-23-252361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312523252361/d534754d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-252361
- JSON: https://secwatch.observer/filing/0001193125-23-252361.json
- Plain text: https://secwatch.observer/filing/0001193125-23-252361.txt

## Key facts
- Debt Financings
  AMGEN INC incurred term loan of $4 billion with Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents.
  - Instrument: term loan
  - Principal: $4 billion
  - Counterparty: Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents
  - Event: incurrence
  source text: On October 6, 2023, Amgen borrowed $4 billion under the Term Loan Credit Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523252361/0001193125-23-252361-index.htm
- M&A Transactions
  AMGEN INC completed an acquisition involving Horizon Therapeutics plc for $116.50 in cash (closed 2023-10-06).
  - Action: acquisition
  - Counterparty: Horizon Therapeutics plc
  - Consideration: $116.50 in cash
  - Closing: 2023-10-06
  source text: of 11:59 p.m. New York City time on October 5, 2023, the business day prior to the occurrence of the Effective Time (the “ Scheme Record Time ”), obtained the right to receive $116.50 in cash in exchange for each Horizon Share (the “ Consideration ”). In respect of the Horizon Shares issued and outstanding as of the Scheme Record Time, Amgen paid an aggregate
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523252361/0001193125-23-252361-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.